GTBP
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- GT Biopharma announced a potential new indication for GTB-5550, a B7-H3-targeted natural killer cell engager, in multiple myelomaSep 15, 2026
- GT Biopharma dosed the first patient in a Phase 1 trial of GTB-5550 targeting B7-H3 in solid tumorsMay 14, 2026
- GT Biopharma received FDA IND clearance for GTB-5550 TriKE NK cell engagerFeb 4, 2026
- GT Biopharma submitted IND for GTB-5550 TriKE NK cell engager targeting B7-H3 tumorsJan 15, 2026
- GT Biopharma provides enrollment update on GTB-3650 Phase 1 trial in patients with relapsed or refractory CD33 expressing hematologic malignanciesOct 9, 2025